Abstract
For decades, HER2-positive breast cancer was associated with poor outcomes and higher mortality rates than other breast cancer subtypes. However, the advent of Trastuzumab (Herceptin) has significantly changed the treatment paradigm of patients afflicted with HER2-positive breast cancer. The discovery of newer HER2-targeted therapies, such as Pertuzumab (Perjeta), has further added to the armamentarium of treating HER2-positive breast cancers. This review highlights recent advancements in the treatment of HER2-positive diseases, including the newer HER2-targeted therapies and immunotherapies in clinical trials, which have paved (and will further update) the way for clinical practice, and become part of the standard of care in the neoadjuvant, adjuvant or metastatic setting.
| Original language | English (US) |
|---|---|
| Article number | 2081 |
| Pages (from-to) | 1-17 |
| Number of pages | 17 |
| Journal | Cancers |
| Volume | 12 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 2020 |
Keywords
- HER2-positive breast cancer
- Immunotherapy
- Metastatic disease
- Neoadjuvant and adjuvant therapy
- Targeted therapy
ASJC Scopus subject areas
- Oncology
- Cancer Research